ASIA GOUT DISEASE TREATMENT MARKET ANALYSIS(2020-2027) - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

ASIA GOUT DISEASE TREATMENT MARKET ANALYSIS(2020-2027)

Description:

Read here the market research report on the “Horse Chestnut Seed Extract Market” published by CMI team – PowerPoint PPT presentation

Number of Views:4
Date added: 3 November 2020
Slides: 19
Provided by: kunalbhuta
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: ASIA GOUT DISEASE TREATMENT MARKET ANALYSIS(2020-2027)


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
ASIA GOUT DISEASE TREATMENT MARKET
ANALYSIS(2020-2027)
  • Asia Gout Disease Treatment Market, By Drug Class
    (Nonsteroidal Anti-inflammatory Drugs (NSAIDs),
    Corticosteroids, Colchicine, and Urate-lowering
    Agents), By Route of Administration (Oral and
    Injectable), By Distribution Channel (Hospital
    Pharmacies, Retail Pharmacies, and Online
    Pharmacies), and By Country (China, India, Japan,
    South Korea, Thailand, Indonesia, Singapore,
    Vietnam, and Rest of Asian Countries) - Size,
    Share, Outlook, and Opportunity Analysis, 2020 -
    2027

3
  • Gout is a condition that is characterized by the
    formation of excess uric acid in body tissues
    that result in the formation of crystals of
    monosodium urate. Symptoms of gout include
    intense pain, swelling, and stiffness in the
    joints. Asia gout disease treatment market is
    expected to witness significant growth due to
    increasing number of pipeline products. For
    instance, Shanton Pharma Co., Ltd, a China-based
    biotech company, has its major drug candidate
    SAP-001 in pipeline. SAP-001 is developed as a
    new investigational Uric Acid Transporter 1
    (URAT1) inhibitor for the chronic management of
    hyperuricemia and gout.

4
  • Asia Gout Disease Treatment Market Impact of
    Coronavirus (Covid-19) Pandemic
  • The Covid 19 pandemic is expected to drive
    growth of the Asia gout disease treatment market
    over the forecast period. Since December 2019, a
    novel coronavirus spread throughout China and
    across the world, causing a continuous increase
    in confirmed cases within a short period of time.
    The disease has spread to more than 100 countries
    across the globe and the World Health
    Organization declared it as a public health
    emergency. For instance, according to the World
    Health Organization Coronavirus Disease
    (COVID-19) Dashboard (WHO) report, the
    manifestation of the coronavirus disease
    (COVID-19) has resulted in more than 11 million
    infected individuals worldwide as of July 2020.

5
  • Furthermore, according to the CreakyJoints, May
    2020, people with gout may be considered in a
    higher-risk group for potential COVID-19
    complications. The coronavirus (COVID 19)
    pandemic and lockdowns in various countries
    across the globe have impacted the financial
    status of businesses across all sectors. The
    private healthcare sector is one the sectors,
    which has been majorly impacted by the COVID 19
    pandemic.
  • The Asia gout disease treatment market is
    estimated to be valued at US 643.55 Million in
    2020 and is expected to exhibit a CAGR of
    9.1 during the forecast period (2020-2027).

6
  • Figure 1 Asia Gout Disease Treatment
    Market Share () Analysis, By Drug Class, 2020

7
  • Asia gout disease treatment market is expected to
    grow significantly in the near future, owing to
    presence of major market players
  • Market players are more focused on adoption of
    inorganic growth strategies such as acquisitions,
    collaborations, and partnerships to strengthen
    their anti-gout drugs portfolio. For instance, in
    September 2019, Simcere Pharmaceutical Group and
    JW Pharmaceutical (both China-based companies)
    entered into a collaboration and exclusive
    license agreement for the development of
    anti-gout drug candidate URC-102 in China. Under
    this agreement, the responsibilities of clinical
    trial and registration will be taken by Simcere
    Pharmaceutical Group. The candidate, URC-102, is
    a selective inhibitor of uric acid transporter
    (URAT-1) and it is in Phase IIb clinical trial in
    patients with gout disease in South Korea.

8
  • Furthermore, big pharmaceutical companies such as
    Takeda Pharmaceutical and AstraZeneca adopted
    inorganic growth strategies. For instance, in
    April 2012, Takeda Pharmaceutical (Japan-based)
    acquired the URL Pharma Inc., a
    Philadelphia-based company, in order to expand
    its gout disease treatment portfolio with the
    acquisition of marketed gout therapy Colcrys
    (colchicine), developed by URL Pharma Inc.
  • Similarly, in December 2018, InventisBio
    announced that it had signed a collaboration
    agreement with Betta Pharma. Under this
    agreement, InventisBio will out-license D-0316's
    rights in China (including mainland China, Hong
    Kong, and Taiwan) to Betta Pharma and to
    co-develop this drug in China. Betta Pharma will
    have the exclusive commercialization rights of
    D-0316 product in China.

9
(No Transcript)
10
  • Asia Gout Disease Treatment Market Restraints
  • The adverse effects and risks associated with
    drugs such as NSAIDS and urate-lowering agents is
    major factor restraining growth of this market.
    Most of the gout drugs are associated with some
    severe side effects, which may lead to decrease
    in demand for these drugs. Nonsteroidal
    anti-inflammatory drugs (NSAIDs) may cause some
    gastric problems such as indigestion. In some
    cases, these drugs can cause gastric ulcers,
    bleeding, and rashes in gastrointestinal GI
    tract. Moreover, side effects such as
    intolerability and contraindication may limit the
    use of these drugs in the treatment of gout.
  • For instance, in February 2019, the U.S. Food and
    Drug Administration (FDA) announced to add a new
    boxed warning for febuxostat, as there is
    increased risk of death associated with Uloric
    (febuxostat) compared to another gout medicine,
    allopurinol. Febuxostat belongs to the
    urate-lowering agents.

11
  • Figure 2 Asia Gout Disease Treatment
    Market Value (US Mn) Y-o-Y Growth (),
    2017-2027

12
  • Asia Gout Disease Treatment Market Competitive
    Landscape
  • Some of the key players operating in the Asia
    gout disease treatment market include AstraZeneca
    Plc, Takeda Pharmaceutical Company Limited,
    Teijin Pharma Limited, Hikma Pharmaceuticals
    Plc., Hikma Pharmaceuticals Plc., Zyla Life
    Sciences, Horizon Therapeutics plc, JW
    Pharmaceutical CORPORATION, and LG Chem.

13
  • Figure 3 Value Chain Analysis

14
  • GCC Medical Gloves Market Competitive Landscape
  • Major players operating in GCC medical gloves
    market include, Paul Hartmann AG, Hotpack
    Packaging Industries, LLC, Falcon (Falcon Pack),
    Top Glove Corp Bhd., Deeko Bahrain, Salalah
    Medical Supplies Mfg. Co. LLC, United Medical
    Industries Co. Ltd., and NAFA (NAFA Enterprises,
    Ltd.).

15
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Reference https//www.coherentmarketinsights.com/
    market-insight/asia-gout-disease-treatment-market-
    4141

16
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

17
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

18
  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com